Advertisement

Topics

NuCana Announces First Patients Enrolled in Phase 2 Study of Acelarin in Platinum-Resistant Ovarian Cancer

09:00 EST 15 Nov 2017 | GlobalNewsWire (2014)

This article has expired, however you can still download the PDF.
Preview:
PRO-105 Study Will Evaluate up to 64 Patients EDINBURGH, United Kingdom, Nov.  15, 2017  (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:NCNA) announced the enrollment of the first patients in both the United States and the United Kingdom in its P...

Other Sources for this Article

NEXT ARTICLE

More From BioPortfolio on "NuCana Announces First Patients Enrolled in Phase 2 Study of Acelarin in Platinum-Resistant Ovarian Cancer"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Women's Health
Women's Health - key topics include breast cancer, pregnancy, menopause, stroke Follow and track Women's Health News on BioPortfolio: Women's Health News RSS Women'...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Ovarian Cancer
Ovarian Cancer is cancer that starts in the female reproductive organs, the ovaries. It is the fifth most common cancer among women.  Women at risk of Ovarian Cancer are those who have had few children (or had children at an older age), carriers o...